© 2003 European Society of Cardiology
Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans
Department of Academic Cardiology, Castle Hill Hospital Cottingham, Kingston upon Hull, HU16 5JQ, UK
* Corresponding author. Tel.: +44-1482-624084; fax: +44-1482-624085. E-mail address: a.p.coletta{at}hull.ac.uk
 |
Abstract |
|---|
The American College of Cardiology provided much useful new information to inform those who care for patients with heart failure about what they should and should not adopt into current clinical practice. The EPHESUS trial suggests a much wider role for aldosterone antagonists for the management of heart failure and left ventricular systolic dysfunction. SPORTIF-III indicates we may have a safer, simpler warfarin substitute soon. ASCOT reinforces the potential futility of statin therapy unless it is well targeted. The results of the COMPANION study investigating cardiac resynchronisation devices and implantable defibrillators were encouraging but inconclusive and/or hard to interpret. UK-PACE again questions the use of dual chamber pacing. T-wave alternans is an interesting experimental technique that may be useful in selecting which patients need an implantable defibrillator, although the technology needs testing in an appropriate patient population.
Key Words: EPHESUS • SPORTIF-III • ASCOT • COMPANION • UK-PACE • T-Wave Alternans
Received April 9, 2003; Accepted April 16, 2003
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Musilli and L. Padeletti Pacemaker selection: time for a rethinking of complex pacing systems? Eur. Heart J., January 2, 2006; 27(2): 132 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. P. Knight, A. Desai, J. Coman, M. Faddis, and P. Yong Long-term retention of cardiac resynchronization therapy J. Am. Coll. Cardiol., July 7, 2004; 44(1): 72 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.L.A.J. Dekker, B. Phelps, B. Dijkman, T. van Der Nagel, F.H. van Der Veen, G.G. Geskes, and J.G. Maessen Epicardial left ventricular lead placement for cardiac resynchronization therapy: Optimal pace site selection with pressure-volume loops J. Thorac. Cardiovasc. Surg., June 1, 2004; 127(6): 1641 - 1647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G.F. Cleland, J. Ghosh, N. Freemantle, G. C. Kaye, M. Nasir, A. L. Clark, and A. P. Coletta Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure Eur J Heart Fail, June 1, 2004; 6(4): 501 - 508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.G. Maessen, B. Phelps, A.L.A.J. Dekker, and B. Dijkman Minimal invasive epicardial lead implantation: optimizing cardiac resynchronization with a new mapping device for epicardial lead placement Eur. J. Cardiothorac. Surg., May 1, 2004; 25(5): 894 - 896. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mukherjee, J. Fang, S. Chetcuti, M. Moscucci, E. Kline-Rogers, and K. A. Eagle Impact of Combination Evidence-Based Medical Therapy on Mortality in Patients With Acute Coronary Syndromes Circulation, February 17, 2004; 109(6): 745 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R J Schilling Non-contact mapping of the left ventricle and new insights into the mechanisms for success of biventricular pacing Heart, January 1, 2004; 90(1): 3 - 4. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G.F. Cleland, N. Freemantle, G. Kaye, M. Nasir, P. Velavan, K. Lalukota, T. Mudawi, R. Shelton, A. L. Clark, and A. P. Coletta Clinical trials update from the American Heart Association meeting: {Omega}-3 fatty acids and arrhythmia risk in patients with an implantable defibrillator, ACTIV in CHF, VALIANT, the Hanover autologous bone marrow transplantation study, SPORTIF V, ORBIT and PAD and DEFINITE Eur J Heart Fail, January 1, 2004; 6(1): 109 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. F. Cleland and A. L. Clark Delivering the cumulative benefits of triple therapy to improve outcomes in heart failure: Too many cooks will spoil the broth J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1234 - 1237. [Full Text] [PDF]
|
|
|
|
|
|
A. P. Coletta, A. L. Clark, A.-M. L. Seymour, and J. G.F. Cleland Clinical trials update from the European Society of Cardiology Heart Failure meeting: COMET, COMPANION, Tezosentan and SHAPE Eur J Heart Fail, August 1, 2003; 5(4): 545 - 548. [Abstract] [Full Text] [PDF]
|
|